Research Article
Inflammatory Markers as Prognostic Factors of Survival in Patients Affected by Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
Table 2
Pretreatment factors affecting progression free survival.
| | | n | mPFS | Univariate | Hazard ratio (95% CI) | Multivariate |
| | Sex | Male | 39 | 10 | 0.4581 | | | | Female | 10 | 12 |
| | Age (years) | >76 | 25 | 15 | 0.9328 | | | | <76 | 24 | 6 |
| | Etiology | HCV | 18 | 10 | 0.1911 | | | | Cripto | 19 | 6 | | Alcol | 10 | 17 | | Others | 2 | 20 |
| | Child-Pugh class | 5 | 17 | 12 | 0.5016 | | | | 6 | 21 | 6 | | 7 | 7 | 15 | | 8 | 3 | — | | 9 | 1 | — |
| | NLR | >2.03 | 25 | 8 | 0.4403 | | | | <2.03 | 24 | 12 |
| | PLR | >87.99 | 25 | 7 | 0.3800 | | | | <87.99 | 24 | 14 |
| | BCLC stage | B | 34 | 10 | 0.1457 | | | | C | 15 | 14 |
| | Tumor size (cm) | >5 | 26 | 12 | 0.9600 | | | | <5 | 23 | 11 |
| | Number of tumors | <3 | 25 | 12 | 0.7320 | | | | 3–5 | 9 | 5 | | >5 | 15 | 10 |
| | Extrahepatic spread | Absent | 49 | 12 | — | | | | Present | 0 | — |
| | Bilobar spread | Absent | 18 | 10 | 0.8673 | | | | Present | 31 | 12 |
| | Ascites | Absent | 37 | 14 | 0.1823 | | | | Present | 12 | 10 |
| | Albumin | >3.7 | 25 | 8 | 0.2176 | | | | <3.7 | 24 | 15 |
| | Bilirubin | >0.84 | 25 | 8 | 0.0841 | | | | <0.84 | 24 | 16 |
| | INR | >1.18 | 25 | 15 | 0.5610 | | | | <1.18 | 24 | 10 |
| | Creatinine | >0.78 | 25 | 5 | 0.0350 | 3.4639 (0.7593–15.8025) | 0.1104 | | <0.78 | 24 | 15 |
| | GFR | >94.5 | 25 | 17 | 0.0429 | 0.6264 (0.1437–2.7311) | 0.5356 | | <94.5 | 24 | 5 |
|
|
Log-rank test; Cox’s proportional hazards regression model.
BCLC = Barcelona Clinic Liver Cancer; Cripto = criptogenetic; GFR = glomerular filtration rate; HCV = hepatitis C virus; INR = International Normalized Ratio; mOS = median overall survival; mPFS = median progression free survival; NLR = neutrophil to lymphocyte ratio; PLR = platelet to lymphocyte ratio.
|
